☰
×
News
Top 20
Insights
Insights+
ThoughtSpot
Interviews
Viewpoints
Exclusive
Spotlight
Events
Magazine
Bespoke
Newswire
x
Search
Search here
Search here
Subscribe Now
NKGen Biotech
NKGen Biotech Reports First Patient Dosing with SNK01 in P-I/IIa Study for Treating Moderate Alzheimer’s Disease
December 29, 2023
NKGen Biotech Collaborated with the Parkinson’s Foundation for Novel Natural Killer Cell Therapy to Treat Advanced Parkinson’s Dis...
November 7, 2022
Load more...
Back to Home
Modal title
×
Modal body text goes here.